Gyre Therapeutics (GYRE) AGM 2026 summary

Opening remarks and agenda

• CEO welcomed shareholders, introduced board members, management, and external advisors.

• Meeting agenda included business items, voting procedures, and rules of conduct.

Shareholder proposals

• Four proposals presented: election of two Class II directors, advisory vote on executive compensation, ratification of auditor, and approval of share issuance upon conversion of Series B preferred stock.

• Board recommended approval of all proposals.

Overview of voting outcomes

• Quorum confirmed with 96.9 million shares outstanding as of record date.

• Polls conducted online; preliminary results indicated all proposals passed.

• Final vote totals to be filed with the SEC.